当前位置: X-MOL 学术J. Appl. Physiol. Gastrointest. Liver Physiol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
GPCRs get Fatty: The Role of G Protein-Coupled Receptor Signaling in the Development and Progression of Nonalcoholic Fatty Liver Disease
American Journal of Physiology-Gastrointestinal and Liver Physiology ( IF 4.5 ) Pub Date : 2020-11-18 , DOI: 10.1152/ajpgi.00275.2020
Ryan Kurtz 1 , Meghan F Anderman 1 , Blythe D Shepard 1
Affiliation  

Non-alcoholic Fatty Liver Disease (NAFLD), characterized by the abnormal deposition of lipids within the liver not due to alcohol consumption, is a growing epidemic affecting over 30% of the US population. Both simple fatty liver and its more severe counterpart, nonalcoholic steatohepatitis (NASH) represent one of the most common forms of liver disease. Recently, several G protein-coupled receptors (GPCRs) have emerged as targets for therapeutic intervention for these disorders. These include those with known hepatic function as well as those involved in global metabolic regulation. In this review, we highlight these emerging therapeutic targets, focusing on several common themes including their activation by microbial metabolites, stimulatory effect on insulin and incretin secretion, and contribution to glucose tolerance. The overlap in ligands, localization, and downstream effects of activation indicate the interdependent nature of these receptors and highlight the importance of this signaling family in the development and prevention of NAFLD.

中文翻译:

GPCRs 变胖:G 蛋白偶联受体信号在非酒精性脂肪肝疾病发展和进展中的作用

非酒精性脂肪性肝病 (NAFLD) 的特点是肝脏内的脂质异常沉积,而不是由于饮酒,它是一种日益流行的流行病,影响超过 30% 的美国人口。单纯性脂肪肝及其更严重的对应物非酒精性脂肪性肝炎 (NASH) 都是最常见的肝病形式之一。最近,一些 G 蛋白偶联受体 (GPCR) 已成为这些疾病治疗干预的靶标。这些包括已知肝功能的那些以及参与全球代谢调节的那些。在这篇综述中,我们重点介绍了这些新兴的治疗靶点,重点关注几个共同的主题,包括微生物代谢物的激活、对胰岛素和肠促胰岛素分泌的刺激作用以及对葡萄糖耐量的贡献。配体的重叠,
更新日期:2020-11-18
down
wechat
bug